• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncNicum.pdf
    Size:
    192.7Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Nicum, S.
    Holmes, J.
    McGregor, N.
    Dunn, R.
    Collins, L.
    Kaye, S.
    McNeish, I.
    Glasspool, R. M.
    Hall, M.
    Roux, R.
    Michael, A.
    Banerjee, S.
    Kristeleit, R.
    Jayson, Gordon C
    Clamp, Andrew R
    Mansouri, A.
    Show allShow less
    Affiliation
    Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background The main aims of the OCTOVA trial were to compare the efficacy and toxicity of olaparib (O) with weekly paclitaxel (wP) and also the oral combination of olaparib plus cediranib (O+C) in recurrent ovarian cancer (OC). Methods Participants with high grade ovarian, fallopian tube, primary peritoneal cancer who relapsed within 12 months of previous platinum-based therapy were randomised, with stratification for germline BRCA1/2 mutation status, prior PARP inhibitor (PARPi) or anti-angiogenic therapy, to receive O (300mg daily) or either wP (80mg/m2 d1,8,15, q28) or O+C (300mg/20mg daily respectively). Treatment continued until disease progression or unacceptable toxicity. Primary endpoint was Progression Free Survival (PFS). Secondary endpoints were safety and tolerability of the combination of O+C, overall survival, objective response rate, and quality of life. A sample size of 138 (46 per arm) was sufficient to observe HR 0.64 in favour of O+C compared to O alone and 1.44 for wP compared to O (20% one-sided type I error, 80% power, 15% dropout, one-sided p-value <0.2). Results OCTOVA recruited 139 participants, median 65 years (IQR:38-84), from 15 UK centres over 34 months. 31 (22%) had had prior PARPi therapy, 47 (34%) prior anti-angiogenic therapy. 41 (29%) had known germline BRCA1/2 mutations. 125 (90%) had relapsed <6 months after prior platinum. Median 2 prior lines of chemotherapy (range 1-7). There was no difference in PFS between wP and O (HR=0.97, 60%CI: 0.79, 1.19; p=0.55). PFS was increased for O+C compared to O (HR=0.70; 60%CI: 0.57, 0.86; p=0.08). There were 239, 176, and 137 treatment related adverse events (all grades) in the O+C, wP and O arms respectively. Conclusions The OCTOVA trial demonstrated that the combination of O+C showed greater efficacy than O alone, but we did not find evidence that wP was inferior to O in women with multiply relapsed OC.
    Citation
    Nicum S, Holmes J, McGregor N, Dunn R, Collins L, Kaye S, et al. 722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S725�6.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624712
    DOI
    10.1016/j.annonc.2021.08.1165
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1165
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1165
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.